Abstract: This invention provides a test for retina lesions. It aims to test whether the retina is damaged by determining whether there are synaptic vesicle proteins in the aqueous humour. The synaptic vesicle proteins include synaptic vesicle protein 2. This invention proposes to determine whether a retina is damaged by determining whether there is synaptic vesicle protein 2 in the aqueous humour. It provides a method to decide the degree to which a retina is damaged in clinic. It is useful to predict the transition from ocular hypertension to glaucoma, so as to cure and preclude glaucoma.

Abstract: The invention discloses a method for treating a disorder or a disease induced by an oxidative stress injury, including administering VEGF-B to a subject; and, a chemical containing VEGF-B protein, VEGF-B expressing plasmids, VEGF-B expressing viruses and/or VEGF-B expressing cells as active ingredients for treating a disorder or a disease induced by an oxidative stress injury. VEGF-B is a strong antioxidant having an intense anti-oxidative effect and capable of up-regulating antioxidant genes and down-regulating oxidant genes, and thus rescuing cellular and vascular degeneration under a pathologic condition. VEGF-B is the first member from the VEGF family to be recognized as a regulatory factor of anti-oxidation pathway, and therefore it can be used as a new medicament for anti-aging and anti-tumor purposes, and for treating varieties of degenerative and oxidative stress injury-related diseases.